Claims
- 1. A 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivative represented by the formula ##STR166## wherein R.sub.1 is a group selected from the class consisting of:
- (a) a COOR.sub.2, wherein R.sub.2 denotes
- (i) hydrogen or a pharmacologically acceptable cation,
- (ii) a straight chain alkyl having 1-12 carbon atoms or a branched alkyl having 3-12 carbon atoms,
- (iii) ##STR167## wherein Z denotes valence bond, or straight chain or branched alkylene which may be represented by C.sub.t H.sub.2t, wherein t denotes an integer of 1-5, further, m denotes an integer of 5-12, R.sub.3 denotes hydrogen or alkyl having 1-5 carbon atoms, and n' denotes an integer of 1-3,
- (iv) --(CH.sub.2 CH.sub.2 O).sub.l CH.sub.3 wherein .sub.l is an integer of 1-5,
- (v) --Z--Ar.sub.1, wherein Z is the same as defined above, Ar.sub.1 denotes phenyl, .alpha.-naphthyl, .beta.-naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, .alpha.-furyl, .beta.-furyl, .alpha.thienyl, .beta.-thienyl or substituted phenyl (wherein the substituent is at least one chlorine, bromine, fluorine, trifluoromethyl, alkyl having 1-4 carbon atoms, nitro, methoxy, phenyl, phenoxy, ##STR168## (vi) --C.sub.l H.sub.2l COOR.sub.3 (vii) --CH.sub.2 CH.sub.l H.sub.2l M(R.sub.3).sub.2 wherein l and R.sub.3 are the same as defined above),
- (viii) ##STR169## wherein R.sub.4 denotes hydrogen or benzoyl and R.sub.5 denotes phenyl, p-bromophenyl, p-biphenyl, p-benzamidophenyl or 2-naphthyl,
- (ix) --C.sub.p H.sub.2p --B', wherein B' is ##STR170## or --C.tbd.C--R.sub.6, wherein R.sub.3 is the same as defined above, R.sub.6 denotes straight chain or branched alkyl having 1-30 carbon atoms, and p is an integer of 1-5, or
- (x) ##STR171## wherein R.sub.7 denotes alkyl or acyl having 1-30 carbon atoms, (b) --CH.sub.2 OH,
- (c) ##STR172## wherein R.sub.11 denotes hydrogen, alkyl having 1-10 carbon atoms, cycloalkyl having 3-12 carbon atoms, phenyl, substituted phenyl, aralkyl having 7-12 carbon atoms or --SO.sub.2 R.sub.12, wherein R.sub.12 denotes alkyl having 1-10 carbon atoms, cycloalkyl having 3-12 carbon atoms, phenyl, substituted phenyl or aralkyl having 7-12 carbon atoms, the two R.sub.11 may be the same or different, however, when one denotes --SO.sub.2 R.sub.12, the other is not --SO.sub.2 R.sub.12, and
- (d) ##STR173## A denotes
- --(CH.sub.2).sub.n --,
- Y denotes hydrogen, chlorine, fluorine, bromine, formyl, methoxy or nitro,
- B denotes to all A and Y
- (i) ##STR174## (ii) ##STR175## further, when Y is chlorine, fluorine, bromine, formyl, methoxy or nitro, B further denotes
- (iii) ##STR176## wherein R.sub.9 denotes hydrogen or alkyl group having 1-4 carbon atoms, R.sub.8 denotes hydrogen, acyl having 1-12 carbon atoms, aroyl having 6-15 carbon atoms, tetrahydropyranyl, tetrahydrofurayl, 1-ethoxy ethyl or t-butyl,
- X denotes
- (i) --CH.sub.2Z CH.sub.2 --,
- (ii) --CH.dbd.CH-- (trans) or
- (iii) --C.tbd.C--
- R.sub.10 denotes
- (i) straight chain alkyl having 4-10 carbon atoms, or
- (ii) ##STR177## wherein Z, m, R.sub.3 and n' are the same as defined above, or (iii) --Z--AR.sub.2, wherein Z is the same as defined above, and Ar.sub.2 denotes phenyl, .alpha.-naphthyl, .beta.-naphthyl or at least one chlorine, bromine, fluorine, trifluoromethyl, alkyl having 1-4 carbon atoms, nitro, methoxy, phenyl or phenoxysubstituted phenyl,
- R.sub.13 denotes
- (i) branched alkyl having 5-10 carbon atoms, or
- (ii) --C.sub.t H.sub.2t OR.sub.14, wherein C.sub.t H.sub.2t is the same as defined above, and R.sub.14 denotes straight chain or branched alkyl having 1-5 carbon atoms, ##STR178## `or --Z--Ar.sub.2, wherein Z, m, R.sub.3, n' and Ar.sub.2 are the same as defined above, or
- (iii) ##STR179## wherein C.sub.t H.sub.2t is the same as defined above, R.sub.15 and R.sub.16 denote hydrogen, methyl, ethyl, propyl or butyl group,
- W denotes
- (i) --CH.sub.2 CH.sub.2 -- or
- (ii) --CH.dbd.CH-- (trans) and the formula (I) denotes d form, l form or dl form.
- 2. A PGI.sub.2 derivative of claim 1 wherein R.sub.2 is a group selected from the class consisting of hydrogen, pharmacologically acceptable cation and --CH.sub.3.
- 3. A PGI.sub.2 derivative of claim 1 wherein B is a group selected from the class consisting of
- (i) ##STR180## and (ii) ##STR181## wherein R.sub.8, R.sub.9, R.sub.10, R.sub.13 and X are the same as defined in claim 1.
- 4. A PGI.sub.2 derivative of claim 3 wherein X is a group selected from the class consisting of --CH.dbd.CH--(trans) and --C.tbd.C--.
- 5. A PGI.sub.2 derivative of claim 3 wherein X is a group selected from the class consisting of --C.dbd.CH--(trans) and --C.tbd.C--, and R.sub.13 is a group selected from the class consisting of
- (i) branched alkyl having 5-10 carbon atoms, and
- (ii) ##STR182##
- 6. A PGI.sub.2 derivative of claim 3 wherein R.sub.10 is a group selected from the class consisting of
- (i) straight chain alkyl having 4-10 carbon atoms, and
- (ii) ##STR183##
- 7. A PGI.sub.2 derivative of claim 3 wherein R.sub.8 is hydrogen and R.sub.9 is hydrogen.
- 8. A PGI.sub.2 derivative of claim 5 wherein t is 3 or 4, R.sub.15 is hydrogen or methyl and R.sub.16 is methyl or ethyl.
- 9. A PGI.sub.2 derivative of claim 3 wherein B is ##STR184## wherein R.sub.10 is ##STR185## wherein m is 5 or 6 R.sub.3 is hydrogen, methyl or ethyl and n' is 1 or 2.
- 10. A PGI.sub.2 derivative of claim 1 wherein
- B is ##STR186## and Y is hydrogen, wherein
- X is --CH.dbd.CH-- or --C.tbd.--,
- R.sub.9 is hydrogen or alkyl group having 1-4 carbon atoms, and R.sub.13 is a group selected from the class consisting of
- (i) branched alkyl having 5-10 carbon atoms, and
- (ii) ##STR187## wherein t, R.sub.15, and R.sub.16 are the same as defined in claim 1.
- 11. A PGI.sub.2 derivative of claim 10 wherein t is 3 or 4 R.sub.15 is hydrogen or methyl, and R.sub.16 is methyl or ethyl.
- 12. A PGI.sub.2 derivative of claim 1 wherein
- B is ##STR188## wherein R.sub.10 is a group selected from the class consisting of (i) straight chain alkyl having 4-10 carbon atoms, and
- (ii) ##STR189## Y is hydrogen, wherein n', R.sub.9, Z, m and R.sub.3 are the same as in claim 1.
- 13. A PGI.sub.2 derivative of claim 12 wherein R.sub.9 is hydrogen, m is 5 or 6, R.sub.3 is hydrogen, methyl or ethyl and n' is 1 or 2.
- 14. A PGI.sub.2 derivative of claim 1 wherein B is ##STR190## wherein R.sub.8, R.sub.9, R.sub.10 and W are the same as defined in claim 1.
- 15. A PGI.sub.2 derivative of claim 14 wherein W is --CH.dbd.CH--(trans).
- 16. A PGI.sub.2 derivative of claim 14 wherein W is --CH.dbd.CH--(trans) and R.sub.10 is a group selected from the class consisting of
- (i) straight chain alkyl having 4-10 carbon atoms, and
- (ii) ##STR191##
- 17. A PGI.sub.2 derivative of claim 14 wherein W is --CH.dbd.CH--(trans), R.sub.9 is hydrogen and R.sub.10 is ##STR192## wherein m is 5 or 6, R.sub.3 is hydrogen, methyl, ethyl or propyl and n' is 1 or 2.
- 18. A PGI.sub.2 derivative of any one of claims 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, wherein R.sub.1 is COOR.sub.2 wherein R.sub.2 is a group selected from the class consisting of hydrogen, pharmacologically acceptable cations and --CH.sub.3.
- 19. 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-16,16-dimethyl PGI.sub.2 or its methyl ester.
- 20. 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(S)-methyl PGI.sub.2 or its methyl ester.
- 21. 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(R)-methyl PGI.sub.2 or its methyl ester.
- 22. 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-16,16-dimethyl-.omega.-homo PGI.sub.2 or its methyl ester.
- 23. 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(S)-methyl-.omega.-homo PGI.sub.2 or its methyl ester.
- 24. 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(R)-methyl-.omega.-homo PGI.sub.2 or its methyl ester.
- 25. 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16,16-dimethyl-16-propoxy PGI.sub.2 or its methyl ester.
- 26. 5,6,7-trinor-4,8-inter-m-phenylene-2,18,19,20-tetranor-16,16-dimethyl-17-ethoxy PGI.sub.2 or its methyl ester.
- 27. 5,6,7-trinor-4,8-inter-m-phenylene-2,18,19,20-tetranor-16,16-dimethyl-17-propoxy PGI.sub.2 or its methyl ester.
- 28. 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16-phenoxy PGI.sub.2 or its methyl ester.
- 29. 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16,16-dimethyl-16-phenoxy PGI.sub.2 or its methyl ester.
- 30. 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16-methyl-16-phenoxy PGI.sub.2 or its methyl ester.
- 31. A pharmaceutical composition for use as an anti-ulcer agent comprising a pharmaceutically acceptable carrier and a PGI.sub.2 derivative of claim 1 in sufficient amount to provide from about 0.001 to about 100 mg of said PGI.sub.2 derivative per dose.
- 32. A pharmaceutically composition for use as an anti-thrombotic agent comprising a pharmaceutically acceptable carrier and a PGI.sub.2 derivative of claim 1 in sufficient amount to provide from about 0.001 to about 50 mg of said PGI.sub.2 derivative per dose.
- 33. A pharmaceutical composition for use as an anti-hypertensive agent comprising a pharmaceutically acceptable carrier and a PGI.sub.2 derivative of claim 1 in sufficient amount to provide from about 0.001 to about 5.0 mg of said PGI.sub.2 derivative per dose.
- 34. A method for treatment of Buerger's disease comprising injecting intravenously a mixture of a pharmaceutically acceptable carrier and a PGI.sub.2 derivative of claim 1, wherein the rate of delivery of said PGI.sub.2 derivative is from about 0.001 to about 100 ng/kg/minute.
Priority Claims (1)
Number |
Date |
Country |
Kind |
56-29357 |
Mar 1981 |
JPX |
|
BACKGROUND OF THE INVENTION
This is a continuation-in-part of application Ser. No. 096,273, filed Sept. 9, 1987, itself a continuation of application Ser. No. 810,011, filed Dec. 12, 1985, now abandoned, itself a continuation in part of application Ser. No. 567,755 filed Jan. 1, 1984, now U.S. Pat. No. 4,564,620 itself a continuation application application Ser. No. 353,875, filed Mar. 2, 1982, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4301164 |
Ohno et al. |
Nov 1981 |
|
4564620 |
Ohno et al. |
Jan 1986 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
810011 |
Dec 1985 |
|
Parent |
353875 |
Mar 1982 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
96273 |
Sep 1987 |
|
Parent |
567755 |
Jan 1984 |
|